NO20092729L - Lipasevarianter for farmasoytisk anvendelse - Google Patents

Lipasevarianter for farmasoytisk anvendelse

Info

Publication number
NO20092729L
NO20092729L NO20092729A NO20092729A NO20092729L NO 20092729 L NO20092729 L NO 20092729L NO 20092729 A NO20092729 A NO 20092729A NO 20092729 A NO20092729 A NO 20092729A NO 20092729 L NO20092729 L NO 20092729L
Authority
NO
Norway
Prior art keywords
lipases
digestive
improved
pharmaceutical use
diabetes
Prior art date
Application number
NO20092729A
Other languages
English (en)
Norwegian (no)
Inventor
Peter-Colin Gregory
Allan Svendsen
Michael Skjot
Debbie Yaver
Lars Lehmann Hylling Christensen
Signe Eskildsen Larsen
Nina Lundin
Michael Lamsa
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of NO20092729L publication Critical patent/NO20092729L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20092729A 2006-12-21 2009-07-20 Lipasevarianter for farmasoytisk anvendelse NO20092729L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87119606P 2006-12-21 2006-12-21
PCT/US2007/087168 WO2008079685A2 (fr) 2006-12-21 2007-12-12 Variantes lipasiques pour une utilisation pharmaceutique

Publications (1)

Publication Number Publication Date
NO20092729L true NO20092729L (no) 2009-09-18

Family

ID=38043020

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092729A NO20092729L (no) 2006-12-21 2009-07-20 Lipasevarianter for farmasoytisk anvendelse

Country Status (16)

Country Link
US (3) US8273348B2 (fr)
EP (6) EP2455461B1 (fr)
JP (1) JP5406040B2 (fr)
KR (1) KR20090101930A (fr)
CN (2) CN105112386A (fr)
AR (1) AR064494A1 (fr)
AU (1) AU2007337150A1 (fr)
BR (1) BRPI0721103A2 (fr)
CA (3) CA3081308C (fr)
IL (1) IL198893A0 (fr)
MX (1) MX2009006597A (fr)
NO (1) NO20092729L (fr)
RU (1) RU2009128067A (fr)
TW (1) TW200829698A (fr)
WO (1) WO2008079685A2 (fr)
ZA (1) ZA200903598B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1729797E (pt) 2004-03-22 2008-12-17 Solvay Pharm Gmbh Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos
CA2616943C (fr) 2005-07-29 2016-04-12 Solvay Pharmaceuticals Gmbh Procede de fabrication de poudre de pancreatine sterilisee
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
CA3081308C (fr) * 2006-12-21 2024-02-20 Novozymes A/S Variantes lipasiques pour une utilisation pharmaceutique
WO2009106553A2 (fr) * 2008-02-29 2009-09-03 Novozymes A/S Variante d’enzyme lipolytique à stabilité améliorée et polynucléotides codant pour cette variante
ES2429492T3 (es) 2008-02-29 2013-11-15 Dsm Ip Assets B.V. Lipasas con alta especificidad hacia ácidos grasos de cadena corta y usos de las mismas
EP2247721A2 (fr) * 2008-02-29 2010-11-10 The Procter & Gamble Company Composition détergente comprenant une lipase
US20140147895A1 (en) 2011-07-22 2014-05-29 Novozymes A/S Processes for Pretreating Cellulosic Material and Improving Hydrolysis Thereof
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
MX2014007612A (es) * 2011-12-29 2014-09-15 Novozymes As Composiciones detergentes con variantes de lipasa.
EP3211074B1 (fr) * 2012-02-03 2020-03-11 Novozymes A/S Variantes de la lipase et polynucléotides les codant
CN104204198B (zh) * 2012-04-02 2018-09-25 诺维信公司 脂肪酶变体以及编码其的多核苷酸
KR20150067336A (ko) * 2012-10-12 2015-06-17 다니스코 유에스 인크. 지방분해 효소 변이체를 포함하는 조성물 및 방법
BR112015028666B8 (pt) * 2013-05-14 2022-08-09 Novozymes As Composição detergente, método para produzir a mesma, método para a limpeza de um objeto e usos da composição
EP3022299B1 (fr) * 2013-07-19 2020-03-18 Danisco US Inc. Compositions et méthodes comprenant un variant d'enzyme lipolytique
WO2016079305A1 (fr) * 2014-11-20 2016-05-26 Novozymes A/S Variants de alicyclobacillus et polynucléotides codant pour ceux-ci
EP4067485A3 (fr) * 2014-12-05 2023-01-04 Novozymes A/S Variantes de la lipase et polynucléotides les codant
EP3230442B1 (fr) 2014-12-09 2019-05-22 Novozymes A/S Variantes de la lipase et polynucléotides les codant
CN107864658A (zh) 2015-04-07 2018-03-30 诺维信公司 用于选择具有脂肪酶活性的酶的方法
EP3317389B1 (fr) * 2015-07-03 2019-04-10 Novozymes A/S Compositions de detergents ayant une stabilite amelioree en presence de sulfites
JP7081767B2 (ja) * 2017-01-30 2022-06-07 学校法人日本医科大学 アデノ随伴ウイルス（ａａｖ）キャプシドタンパク質の変異体
CN111356762A (zh) * 2017-09-27 2020-06-30 诺维信公司 脂肪酶变体和包含此类脂肪酶变体的微囊组合物
EP3461892A3 (fr) * 2017-09-27 2019-06-12 The Procter & Gamble Company Compositions détergentes comprenant des lipases
WO2019154954A1 (fr) * 2018-02-08 2019-08-15 Novozymes A/S Variants de lipase et compositions en comprenant
CN111334369B (zh) * 2020-03-11 2022-10-21 陕西科技大学 一种酶法制备卵磷脂型pufa的方法
BR112023008326A2 (pt) * 2020-10-29 2023-12-12 Novozymes As Variantes de lipase e composições compreendendo tais variantes de lipase
CN113846074B (zh) * 2021-10-20 2022-10-21 南京林业大学 一种疏棉状嗜热丝孢菌脂肪酶突变体g91c及其应用
WO2023225459A2 (fr) 2022-05-14 2023-11-23 Novozymes A/S Compositions et procédés de prévention, de traitement, de suppression et/ou d'élimination d'infestations et d'infections phytopathogènes

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173590D0 (da) * 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
US5869438A (en) 1990-09-13 1999-02-09 Novo Nordisk A/S Lipase variants
JP3469234B2 (ja) * 1990-09-13 2003-11-25 ノボザイムス アクティーゼルスカブ リパーゼ変異体
DK46693D0 (fr) 1993-04-23 1993-04-23 Novo Nordisk As
WO1992010755A1 (fr) 1990-12-05 1992-06-25 Novo Nordisk A/S Proteines presentant des epitopes modifies et procedes de preparation de ces proteines
WO1992019726A1 (fr) 1991-05-01 1992-11-12 Novo Nordisk A/S Enzymes stabilisees
DK39693D0 (da) 1993-04-02 1993-04-02 Novo Nordisk As Enzym
JPH09503130A (ja) 1993-10-04 1997-03-31 ノボ ノルディスク アクティーゼルスカブ 修飾酵素を含んで成る酵素調製品
CN1077598C (zh) 1994-02-22 2002-01-09 诺沃奇梅兹有限公司 制备脂解酶变异体的方法
WO1996016177A1 (fr) 1994-11-24 1996-05-30 Novo Nordisk A/S Procede de production de polypeptides a allergenicite reduite
CA2206852A1 (fr) 1994-12-07 1996-06-13 Novo Nordisk A/S Polypeptide a allergenicite reduite
EP0805856B2 (fr) 1995-01-26 2009-04-01 Novozymes A/S Additifs pour l'alimentation animale, comportant de la xylanase
US6495357B1 (en) 1995-07-14 2002-12-17 Novozyme A/S Lipolytic enzymes
CN1193346A (zh) 1995-07-14 1998-09-16 诺沃挪第克公司 一种具有脂解活性的修饰酶
ES2221934T3 (es) 1995-08-11 2005-01-16 Novozymes A/S Nuevas enzimas lipoliticas.
JP2002510963A (ja) 1997-01-10 2002-04-09 ノボザイムス アクティーゼルスカブ スキンケア用酵素修飾体
CA2279986A1 (fr) 1997-02-06 1998-08-13 Novo Nordisk A/S Conjugats polypeptide-polymere a groupes de fixation ajoutes et/ou retires
AU751880B2 (en) 1997-06-25 2002-08-29 Novozymes A/S A modified polypeptide
ATE328070T1 (de) * 1998-02-17 2006-06-15 Novozymes As Lipasevariante
AU3247699A (en) 1998-02-17 1999-09-06 Novo Nordisk A/S Lipase variant
AU6078899A (en) 1998-10-13 2000-05-01 Novozymes A/S A modified polypeptide with reduced immune response
JP2003500003A (ja) 1998-10-30 2003-01-07 ノボザイムス アクティーゼルスカブ 低いアレルゲン性のタンパク質変異型
JP2002531067A (ja) 1998-10-30 2002-09-24 ノボザイムス アクティーゼルスカブ 低下したアレルゲン性を有するグリコシル化タンパク質
EP1131416B1 (fr) 1998-11-27 2009-09-02 Novozymes A/S Variants d'enzyme lipolytique
US7312062B2 (en) * 1998-11-27 2007-12-25 Novozymes A/S Lipolytic enzyme variants
DK1162995T3 (da) 1999-03-17 2003-06-23 Solvay Pharm Gmbh Enzymer til behandling af diabetes mellitus type I
EP1171581A1 (fr) * 1999-03-31 2002-01-16 Novozymes A/S Variante genetique de lipase
EP2278000A1 (fr) * 1999-03-31 2011-01-26 Novozymes A/S Variante de lipase
KR20020083157A (ko) 2000-02-08 2002-11-01 에프. 호프만-라 로슈 아게 동물 사료에서 산-안정성 프로테아제의 사용
WO2001083559A2 (fr) 2000-04-28 2001-11-08 Novozymes A/S Variants de protéines à immunogénicité modifiée
ATE426668T1 (de) * 2001-01-10 2009-04-15 Novozymes As Variante eines lipolytischen enzyms
AR032392A1 (es) 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
EP1360278B1 (fr) 2001-02-07 2009-09-23 Novozymes A/S Variantes de lipase
WO2003060112A1 (fr) * 2002-01-16 2003-07-24 Novozymes A/S Variants d'enzymes lipolytiques et procede de production
JP2007506405A (ja) 2003-02-06 2007-03-22 ノボザイムス アクティーゼルスカブ 糸状菌におけるヒトｈ鎖抗体の発現
EP2290057A3 (fr) 2003-05-09 2011-08-03 Novozymes A/S Enzymes lipolytiques variants
EP1639107B1 (fr) 2003-06-19 2013-08-14 Novozymes A/S Proteases ameliorees et procedes de production de ces dernieres
EP1639102A2 (fr) 2003-06-19 2006-03-29 Novozymes A/S Variantes genetiques de la phospholipase
JP2007535913A (ja) 2004-01-21 2007-12-13 ノボザイムス アクティーゼルスカブ ヘテロカリオン菌類又は菌類宿主細胞におけるモノクローナル抗体の生成
PT1729797E (pt) 2004-03-22 2008-12-17 Solvay Pharm Gmbh Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos
SI1809320T1 (sl) 2004-10-14 2010-11-30 Cystic Fibrosis Foundation Therapeutics Inc Sestavki ki vsebujejo lipazo proteazo in amilazo za zdravljenje pankreasne insuficience
US20080138856A1 (en) 2005-02-10 2008-06-12 Novozymes A/S Enzymatic Enantioselective Ester or Amide Hydrolysis or Synthesis
JP2008546394A (ja) * 2005-06-24 2008-12-25 ノボザイムス アクティーゼルスカブ 医薬使用のためのリパーゼ
US20080317726A1 (en) 2005-06-24 2008-12-25 Novozymes A/S Proteases for Pharmaceutical Use
BRPI0611932A2 (pt) 2005-06-24 2011-01-04 Novozymes As amilase, uso da mesma, composição farmacêutica, e, método para o tratamento de uma doença
WO2007080197A2 (fr) * 2006-01-16 2007-07-19 Novozymes A/S Enzymes immobilisees
CN101370921B (zh) * 2006-01-23 2014-08-13 宝洁公司 包含脂肪酶和漂白催化剂的组合物
EP1979477B1 (fr) * 2006-01-23 2017-04-19 Novozymes A/S Variantes de lipase
CA3081308C (fr) * 2006-12-21 2024-02-20 Novozymes A/S Variantes lipasiques pour une utilisation pharmaceutique

Also Published As

Publication number Publication date
EP2261328A1 (fr) 2010-12-15
AR064494A1 (es) 2009-04-08
EP2455461A3 (fr) 2013-05-29
EP2455461B1 (fr) 2016-03-16
IL198893A0 (en) 2010-02-17
CA3081308C (fr) 2024-02-20
CN101743308A (zh) 2010-06-16
JP2010512795A (ja) 2010-04-30
EP2261328B1 (fr) 2013-11-20
BRPI0721103A2 (pt) 2014-03-04
EP2455462B1 (fr) 2016-03-16
EP2455459A2 (fr) 2012-05-23
US9029115B2 (en) 2015-05-12
CN105112386A (zh) 2015-12-02
EP2455460A3 (fr) 2012-12-26
EP2455462A2 (fr) 2012-05-23
EP2455459A3 (fr) 2013-04-24
CA2670643A1 (fr) 2008-07-03
WO2008079685A3 (fr) 2008-11-06
EP2455462A3 (fr) 2013-05-29
JP5406040B2 (ja) 2014-02-05
MX2009006597A (es) 2009-07-02
US20120308543A1 (en) 2012-12-06
US8273348B2 (en) 2012-09-25
EP2099907A2 (fr) 2009-09-16
WO2008079685A2 (fr) 2008-07-03
CN101743308B (zh) 2015-09-16
EP2455461A2 (fr) 2012-05-23
KR20090101930A (ko) 2009-09-29
CA2961041C (fr) 2020-07-14
ZA200903598B (en) 2010-04-28
US9539311B2 (en) 2017-01-10
AU2007337150A1 (en) 2008-07-03
CA2961041A1 (fr) 2008-07-03
EP2455460A2 (fr) 2012-05-23
US20150209414A1 (en) 2015-07-30
CA2670643C (fr) 2017-04-25
US20100034797A1 (en) 2010-02-11
EP2455459B1 (fr) 2016-03-16
CA3081308A1 (fr) 2008-07-03
TW200829698A (en) 2008-07-16
RU2009128067A (ru) 2011-01-27

Similar Documents

Publication Publication Date Title
NO20092729L (no) Lipasevarianter for farmasoytisk anvendelse
NO20080437L (no) Lipaser til farmasoytisk anvendelse
McClellan et al. Cellular functions and molecular mechanisms of non-lysine ubiquitination
Draganov Lactonases with oragnophosphatase activity: structural and evolutionary perspectives
Cornaciu et al. The minimal domain of adipose triglyceride lipase (ATGL) ranges until leucine 254 and can be activated and inhibited by CGI-58 and G0S2, respectively
Candas et al. MnSOD in oxidative stress response-potential regulation via mitochondrial protein influx
DK1755656T3 (da) Enzymer til farmaceutisk anvendelse
NO20080439L (no) Amylaser til farmasoytisk anvendelse
Chandrasekaran et al. In search of a catalytic bioscavenger for the prophylaxis of nerve agent toxicity
NL300874I2 (nl) Elosulfase alfa
JP2010512795A5 (fr)
NO20080438L (no) Proteaser til farmasoytisk anvendelse
DK1162995T3 (da) Enzymer til behandling af diabetes mellitus type I
EP4241854A3 (fr) Enzyme des maladies lysosomales
MX2010005690A (es) Variantes de proteasa para uso farmaceutico.
US11584920B2 (en) Use of enzymes with a wide pH activity range as medicaments for promoting digestion
Mandrich et al. Hyperthermophilic phosphotriesterases/lactonases for the environment and human health
Park et al. Catalytic properties of the PepQ prolidase from Escherichia coli
Taylor et al. Cholinesterase confabs and cousins: approaching forty years
TH88730A (th) ไลเปสสำหรับการใช้ทางเภสัชกรรม
TH105721B (th) แวเรียนท์ของไลเปสสำหรับการใช้ทางเภสัชกรรม
TH105721A (th) แวเรียนท์ของไลเปสสำหรับการใช้ทางเภสัชกรรม
WO2008040739A3 (fr) Variants d'enzymes lipolytiques
Roy et al. Expression of recombinant human cathepsin K is enhanced by codon optimization
Lin et al. Benzene-di-N-octylcarbamates as conformationally constrained phospholipase A2 inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application